Filing summary
Entity and period mismatch: The supplied metadata identifies Lisata Therapeutics, Inc. and 2020 Q3, but the filing text is Caladrius Biosciences, Inc.’s Form 10-Q for the quarter ended September 30, 2021. This summary reflects the filing text.
Business context
Caladrius is a clinical-stage biopharmaceutical company developing autologous CD34+ cell therapies. Its programs include XOWNA for coronary microvascular dysfunction (CMD), HONEDRA for critical limb ischemia and Buerger’s disease, and CLBS201 for diabetic kidney disease. The company reported no revenue in the periods presented.
Key financial metrics
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Operating expenses | $7.0 million | $5.4 million | $22.2 million | $13.7 million |
| Net loss | $6.9 million | $5.3 million | $20.7 million | $2.7 million |
| Operating cash used | Not presented quarterly | Not presented quarterly | $17.6 million | $3.3 million |
| Basic and diluted loss per share | $0.12 | $0.29 | $0.38 | $0.19 |
At September 30, 2021, cash and cash equivalents were $12.8 million and marketable securities were $87.4 million, totaling approximately $100.1 million in cash, cash equivalents, and marketable securities. Working capital was approximately $98.0 million; total liabilities were $4.1 million, with no debt balance identified in the provided financial statements. Stockholders’ equity was $98.4 million, including noncontrolling interests.
Changes versus comparable periods
- Q3 operating expenses rose 30% year over year, principally as research and development spending increased for the XOWNA Phase 2b FREEDOM Trial; higher D&O insurance and strategic consulting also increased general and administrative expense.
- Nine-month operating expenses increased 62%, with research and development expense more than doubling to $13.5 million.
- Nine-month net loss widened to $20.7 million from $2.7 million. The comparison is affected by a $10.9 million income tax benefit from the sale of New Jersey net operating losses recorded in 2020; 2021 included a $1.5 million tax benefit from a separate sale.
- Nine-month operating cash use increased to $17.6 million. Financing provided $85.3 million, mainly from January and February 2021 equity-and-warrant offerings; net proceeds from common-stock issuance were $85.5 million.
- Shares outstanding increased from 19.4 million at December 31, 2020 to 59.8 million at September 30, 2021. Warrants outstanding rose to 21.4 million, creating potential additional dilution.
Outlook, commentary, and risks
- Management said existing cash was expected to fund operating expenses for at least the next 12 months after issuance of the financial statements. It also warned that additional capital may be needed and may not be available on acceptable terms or at all. A $50 million ATM facility was available, but no shares had been sold under it by September 30, 2021.
- XOWNA’s Phase 2b trial enrollment slowed amid COVID-19 impacts. Protocol amendments were implemented to try to broaden and accelerate enrollment; management planned to assess enrollment improvement in Q4 2021.
- HONEDRA enrollment in Japan was suspended because of COVID-related delays and the associated operational and financial burden. The company was seeking a Japanese partner and considering whether existing data could support a submission under Japan’s SAKIGAKE pathway; neither outcome was assured. The company also said it would not pursue U.S. development of CLBS12 for Buerger’s disease at that time.
- CLBS201 was being planned as a six-subject Phase 1 proof-of-concept study, with enrollment projected to begin in Q1 2022, subject to IRB approval. Continued development depends on demonstrating a therapeutic effect.
- COVID-19, trial enrollment and execution, regulatory outcomes, financing availability, and the ability to secure partnerships or realize licensing value remain material uncertainties. The filing reported no material changes to previously disclosed risk factors and no material legal proceedings or off-balance-sheet arrangements.
Important facts to verify
- Confirm the intended company and reporting period: the supplied filing is Caladrius Biosciences’ Q3 2021 10-Q, not a Lisata Therapeutics Q3 2020 filing.
- Review cash runway assumptions and actual operating cash burn against management’s stated 12-month funding expectation.
- Track FREEDOM Trial enrollment, CLBS201 study approvals and timing, and any HONEDRA partnership or PMDA submission developments.
- Assess dilution from the 2021 equity and warrant issuances, outstanding warrants, and any future ATM sales.